XELOX for Metastatic Breast Cancer

A Phase II Trial of Capecitabine and Oxaliplatin in Metastatic Breast Cancer

Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.

Inclusion Criteria:

• preserved organ function
• good performance status
• no more than one prior therapy
• no active brain metastasis

Exclusion Criteria:

• No prior capecitabine or oxaliplatin
• no con-current therapy